xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
Company profile
Ticker
XERS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Xeris Pharmaceuticals, Inc. • Xeris Pharmaceuticals Australia Pty Ltd • Strongbridge Biopharma Limited • Strongbridge Dublin Limited • Cortendo AB ...
XERS stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
6 Mar 24
8-K
Xeris Biopharma Updates Its Outlook for 2023
4 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Xeris Biopharma Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
8-K
Entry into a Material Definitive Agreement
29 Sep 23
8-K
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
27 Sep 23
10-Q
2023 FY
Quarterly report
8 Aug 23
Transcripts
XERS
Earnings call transcript
2023 Q4
6 Mar 24
XERS
Earnings call transcript
2023 Q3
9 Nov 23
XERS
Earnings call transcript
2023 Q2
8 Aug 23
XERS
Earnings call transcript
2023 Q1
9 May 23
XERS
Earnings call transcript
2022 Q4
8 Mar 23
XERS
Earnings call transcript
2022 Q3
9 Nov 22
XERS
Earnings call transcript
2022 Q2
10 Aug 22
XERS
Earnings call transcript
2022 Q1
11 May 22
XERS
Earnings call transcript
2021 Q4
10 Mar 22
XERS
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
JEFFREY W SHERMAN
11 Apr 24
4
Garheng Kong
1 Apr 24
4
JOHN JOHNSON
1 Apr 24
4
JOHN JOHNSON
18 Mar 24
4
John P. Schmid
14 Mar 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
4
Steven Pieper
31 Jan 24
4
John Patrick Shannon Jr
31 Jan 24
4
KENNETH ERLAND JOHNSON
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.57 mm | 50.57 mm | 50.57 mm | 50.57 mm | 50.57 mm | 50.57 mm |
Cash burn (monthly) | 9.00 k | 2.80 mm | 1.64 mm | 4.11 mm | 4.87 mm | 5.88 mm |
Cash used (since last report) | 60.05 k | 18.65 mm | 10.93 mm | 27.43 mm | 32.49 mm | 39.26 mm |
Cash remaining | 50.51 mm | 31.92 mm | 39.64 mm | 23.14 mm | 18.08 mm | 11.31 mm |
Runway (months of cash) | 5612.1 | 11.4 | 24.2 | 5.6 | 3.7 | 1.9 |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Johnson John | Common Stock | Option exercise | Acquire M | No | No | 1.99 | 215,600 | 429.04 k | 751,412 |
18 Mar 24 | Johnson John | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.99 | 215,600 | 429.04 k | 0 |
15 Mar 24 | Kong Garheng | Common Stock | Other | Acquire J | No | No | 0 | 6,474 | 0.00 | 114,144 |
15 Mar 24 | Johnson John | Common Stock | Other | Acquire J | No | No | 0 | 89,571 | 0.00 | 840,983 |
15 Mar 24 | Jeffrey W Sherman | Common Stock | Other | Acquire J | No | No | 0 | 6,502 | 0.00 | 114,380 |
14 Mar 24 | Schmid John P. | Common Stock | Buy | Acquire P | Yes | No | 2.16 | 4,500 | 9.72 k | 11,000 |
News
Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5
28 Mar 24
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $6
7 Mar 24
Xeris Biopharma Holdings Q4 GAAP EPS $(0.10), Inline, Sales $44.39M Beat $43.55M Estimate
6 Mar 24
Earnings Scheduled For March 6, 2024
6 Mar 24
Earnings Outlook For Xeris Biopharma Holdings
5 Mar 24
Press releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 Apr 24
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
6 Mar 24
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
6 Mar 24
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
5 Feb 24